Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.

The article focuses on a research which aims to evaluate the efficacy of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients following lenalidomide and bortezomib therapy or who were ineligible to receive such drugs as measured by the rate of response in terms of overall response rate. It also aims to assess the tolerability and toxicity and evaluate the time to treatment failure, overall survival, and disease-free survival.